Pregnant and postpartum women face dual jeopardy when battling opioid addiction—their lives and their babies' development hang in the balance with every potential overdose. Yet the most basic safety net, naloxone access, appears catastrophically inadequate during this critical window. Analysis of clinical data spanning seven years reveals a troubling gap between overdose risk and prevention readiness in maternal care settings.
The MAT-LINK network study examined naloxone prescribing patterns among women with opioid use disorder across seven clinical sites from 2014 to 2021. Among pregnant and postpartum women receiving treatment, only 3.1 percent obtained naloxone prescriptions during the perinatal period. The research documented that women experiencing overdose events were predominantly non-Hispanic white individuals with public insurance living in urban areas. Co-occurring substance use was common, with over 80 percent using tobacco and nearly 60 percent having stimulant use disorders alongside their opioid dependency.
This prescribing rate represents a stark disconnect between clinical guidelines and practice implementation. Naloxone availability has become standard care for most opioid-dependent populations, yet pregnant women—arguably among the highest-stakes cases—remain systematically underserved. The findings suggest institutional hesitation around addiction management during pregnancy, possibly reflecting provider discomfort with dual maternal-fetal considerations. This gap becomes more concerning when considering that pregnancy often involves medication adjustments that could alter overdose susceptibility. While the study couldn't capture informal naloxone distribution, the formal prescription data indicates missed opportunities for systematic harm reduction. Addressing this disparity requires targeted protocols ensuring pregnant women receive the same overdose prevention resources available to other vulnerable populations.